Radiochemical separation and chelation of Sc-44
Aeli Olson (1), Eduardo Aluicio-Sarduy (1), Lily Li (2), Thomas Kostelnik (2), Reinier Hernandez (1), Dawei Jiang (1), Emily Ehlerding (1), Todd Barnhart (1), Valery Radchenko (3), Paul Schaffer (3), Weibo Cai (1), Jonathan Engle (1)
(1) Department of Medical Physics, University of Wisconsin, B1303 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA, (2) Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, Vancouver BC, V6T 1Z1, Canada, (3) Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver BC, V6T 243, Canada
Oral Presentation
the authors have no conflicts of interest to declare
Recently approved by the United States Food and Drug Administration, 177Lu-DOTA-TATE has been proven an effective agent for targeted radionu-clide therapy of gastroenteropancreatic neuro-endocrine tumors. Though 177Lu (6.65 d, 100% – decay) is a promising therapy radionuclide, luteti-um does not afford a viable positron-emitting diagnostic radioisotope. Multiple positron emit-ting lutetium radioisotopes exist but have low positron intensities and high energy gamma emissions, making them dosimetrically undesirable.
Gallium and scandium have positron emitting radioisotopes and are commonly thought to be suitable imaging surrogates of 177Lu in theranostic applications. Preclinical investigations comparing the two have found that in vivo, scandium more closely mimics the distribution kinetics of lutetium. The growing interest in 44Sc (3.97 h, 94% + decay) and 47Sc (3.35 d, 100% – decay) motivated this attempt to refine the radiochemical separation from calcium cyclotron targets and to identify novel ligands for scandium chelation.